



SOLUTIONS TO ADVANCE PARKINSON'S DISEASE TREATMENT STUDIES

Parkinson's disease studies face unique challenges. For one, patients often suffer from disabling neuropsychiatric symptoms that can make study participation difficult. The effective and efficient collection of remote, patient-reported data and digital outcomes is often required in today's studies. Finally, the reliability of clinician-reported outcomes, and the expertise to interpret the data, is critical to detect signals. That's where Signant Health's solutions can help.

IMPROVE SIGNAL DETECTION

With blinded data analytics, our clinicians and scientists use analytics powered by proprietary algorithms to identify inconsistencies in ratings, in real-time, to drive high quality and reliable clinical outcome assessment data.

SUPPORT PATIENT NEEDS

Offering the same quality of in-person evaluations, SmartSignals Telemedicine can be used to reduce the number of site visits required in a study. Displaying large, well-spaced buttons that can be tapped with knuckle or fingertip, our patient-reported outcome measures make it easier for patients with motor symptoms to respond.

GAIN RICHER INSIGHTS

Integrating activity monitoring with eCOA enables objective measurement of sleep and physical activity to be included alongside patient and clinician assessments.

COMMON SCALES USED IN PARKINSON'S DISEASE CLINICAL TRIALS

- UPDRS (MDS)
- Hoehn & Yahr Scale
- PDQ-39
- PD NMS
- PDSS-2
- Parkinson's Motor Diary

ASK US FOR A COMPLETE LIST.

ACHIEVE OPTIMAL ENDPOINT QUALITY

SmartSignals Rater Training & Qualification and Endpoint Solutions are fully customizable programs that train and monitor raters on the study-specific outcome measures for the most consistent endpoints. Our industry-leading scientific and clinical teams are dedicated to ensuring that primary and key outcomes are reliably administered and scored throughout a study.

OPTIMIZE DATA COLLECTION

Our motor diary, a key component of our eCOA solution, uses an electronic, screen-based format to collect data at scheduled times, while completion windows prohibit entries outside of the determined recall period.

DIGITALIZE THE ENTIRE PROCESS

While all of our SmartSignals solutions can be used as standalone tools, they integrate with one another to further enhance the accuracy and efficiency in your Parkinson's disease study.

At Signant Health, our SmartSignals solution suite was designed specifically to meet the needs of sponsors, sites, and Parkinson's disease patients. Make sure your findings are reliable with today's latest technology.

SIGNANT'S PARKINSON'S DISEASE CLINICAL RESEARCH EXPERIENCE

Phases



16
Languages



1,600+
Sites



15
Countries



4,397
Patients



52
Trials

SMARTSIGNALS™ TRIAL SOLUTIONS

eCOA | ELECTRONIC CLINICIAN RATINGS | eCONSENT
PATIENT CONCIERGE | BLINDED DATA ANALYTICS | RATER TRAINING & QUALIFICATION

MEET THE EXPERTS

Discuss your next Parkinson's disease study with our subject matter experts, and we'll tailor our solutions to fit your needs.



BILL BYROM, PhD

*VP Product Intelligence
& Positioning*

Bill has worked in the pharmaceutical industry for 30 years and authored of over 70 publications as well as two industry textbooks on electronic patient-reported outcomes (ePRO).



DAN DEBONIS

Principal Endpoint Solutions

Dan is one of the pioneers and leaders at the forefront of innovation for eCOA, outcome analytics, and the integration of digital technologies in clinical research. He is the author of a patent and publications on technologies in clinical research.



JILL PLATKO, PhD

Senior Scientific Advisor

Jill is an expert in electronic Clinical Outcome Assessment (eCOA) systems. She began her career in biology-based scientific research and led projects for over 16 years at renowned institutions, such as Cornell University and Massachusetts General Hospital.

CONTACT US TO LEARN HOW SIGNANT HEALTH CAN SUPPORT YOUR NEXT STUDY.